14 results about "Aceglutamide" patented technology

The present application relates to the technical field of biocatalysis and biosynthesis, and specifically discloses a natural blue pigment and a biosynthesis method therefor. The present application uses metabolically engineered bacteria to express indigoidine synthetase and phosphopantetheinyl transferase, to catalyze glutamine and N-acetylglutamine to biosynthesize a natural blue pigment N-acetylindigoidine, and deduces its molecular structure by means of mass spectrometry, nuclear magnetic resonance and other methods. The present application achieves catalytic synthesis of N-acetylindigoidine from glutamine and N-acetylglutamine in Escherichia coli, Corynebacterium glutamicum, Saccharomyces cerevisiae and Streptomyces. Compared with indigoidine, N-acetylindigoidine has a maximum absorption wavelength of 584 nm, possesses better color brightness, and has more stable coloration that is not easily faded, with a very broad application range and industrial production application prospects.

The present application relates to the technical field of biocatalysis and biosynthesis, and specifically discloses a blue pigment and a biosynthesis method thereof. In the present application, an indigoidine synthetase and a 4′-phosphopantetheinyl transferase are expressed by a metabolically engineered strain to catalyze the biosynthesis of the blue pigment N-acetyl-indigoidine from glutamine and N-acetylglutamine, and a molecular structure of the blue pigment is inferred by mass spectrometry, nuclear magnetic resonance spectroscopy, etc. The present application achieves the catalytic synthesis of N-acetyl-indigoidine from glutamine and N-acetylglutamine in Escherichia coli (E. coli), Corynebacterium glutamicum (C. glutamicum), Saccharomyces cerevisiae (S. cerevisiae), and Streptomyces. Compared with indigoidine, N-acetyl-indigoidine has a maximum absorption wavelength of 584 nm, and a stable color having high brightness that is not easy to fade. Thus, the blue pigment shows an extensive application range and a promising industrial production prospect.

The invention discloses a continuous flow synthesis method of chloracetyl-L-glutamine and glycyl-glutamine, and belongs to the technical field of organic synthesis. According to the invention, molecular-level efficient mixing and heat conduction of materials are realized, so that the reaction materials are fully mixed, the reaction is more sufficient, the conversion rate is further improved, and the process operation is safe and controllable. The micro-channel reactor has the advantages that equipment is relatively small, the reaction is continuous flow, the feed flux is large, the occupied area of the equipment is reduced, and the productivity is improved. Through a micro-channel continuous flow method, ammonia water or ammonia gas is directly adopted without adding ammonium bicarbonate, the problem that the ammonia water cannot be used mechanically is solved, the recycled ammonia water treated after reaction can be directly used mechanically, three wastes are thoroughly solved, and the production process is green and environment-friendly. The glycyl-L-glutamine is totally synthesized through micro-channel continuous flow, the product purity HPLC (High Performance Liquid Chromatography) of the glycyl-L-glutamine reaches 99.5% or above, and the single impurity content is less than 0.1%.

The invention relates to the field of traditional Chinese medicine, in particular to application of phenylacetyl glutamine as a marker in preparation of a product for diagnosing and / or treating damp-heat syndrome of diabetes. The invention finds that the PAGln in the plasma and urine of a patient with the damp-heat syndrome of diabetes is increased, and the PAGln can be used as a biomarker for dialectical treatment of the damp-heat syndrome of diabetes.

Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.

The invention discloses an application of N-Aceglutamide (NAG) in preparation of a medicine for treating obesity or relieving obesity-related metabolic indexes or metabolism-related fatty liver (MAFLD) (Metabolism-related Fatty Liver Disease). The invention further discloses an application of the N-Aceglutamide (NAG) in preparation of a medicine for treating obesity or relieving obesity-related metabolic indexes or metabolism-related fatty liver (MAFLD). According to the invention, the important application prospect of NAG in weight reduction and treatment of MAFLD diseases is shown for the first time, fat weight can be reduced, obesity can be treated, and NAG can significantly reduce fat tissue accumulation, promote lipolysis, inhibit adipogenesis and reduce serum triglyceride and free fatty acid levels. In animal models, NAG significantly reduces weight gain induced by high fat diet and improves body fat distribution. The NAG disclosed by the invention can effectively avoid side effects such as nausea, vomiting, constipation and the like caused by weight loss medicines such as appetite inhibition or food intake reduction, and an effective medicine is provided for MAFLD treatment.

This invention relates to a kit for predicting the risk of gestational diabetes mellitus in subjects and its application. The kit includes reagents for detecting the levels of biomarkers in biological samples, wherein the biomarkers are selected from one or more of trimethylamine oxide and its precursor compounds and phenylacetylglutamine. The biomarker detection method of this invention for predicting gestational diabetes mellitus requires a small serum volume and only a single test, reducing the waiting time for pregnant women. It is anticipated that the clinical use of the biomarkers of this invention as detection targets can reduce the adverse effects of late-onset gestational diabetes mellitus on both the mother and newborn.

The invention relates to the technical field of microbial fermentation, and particularly discloses a natural haematochrome and a fermentation process thereof. According to the present invention, the fermentation process is innovated, the pH value is regulated to induce the engineering bacteria so as to convert the glutamic acid into the N-acetylglutamine, and the N-acetylglutamine is artificially added to inhibit the generation of the N-acetyl-observation blue product and promote the generation of the N, N '-diacetyl-observation blue (natural haematochrome); compared with a natural blue pigment N-acetyl-observation blue, the natural red pigment N, N '-diacetyl-observation blue has the maximum absorption wavelength of 499 + / -2nm, and the colored light of the natural red pigment N, N'-diacetyl-observation blue can be used as one of three primary colors, can be used for dyeing, and also can be matched with other colors of dyes.

This invention discloses a method for constructing an animal model of sensorineural hearing loss induced by phenylacetylglutamine and its application. The method includes: selecting 6-8 week old male C57BL / 6J mice, intraperitoneally injecting phenylacetylglutamine solution at a dose of 50 mg / kg body weight / day, once daily, for at least 4 months to obtain the sensorineural hearing loss animal model. This model is characterized by a significantly elevated auditory brainstem response threshold, loss of cochlear outer hair cells, and increased oxidative stress levels. This invention establishes for the first time an animal model of sensorineural hearing loss induced by the circulating metabolite phenylacetylglutamine, filling the technical gap in existing models that cannot simulate hearing loss mediated by metabolic abnormalities. The model construction method is simple to operate, has a high success rate, and good reproducibility, and can be used for research on the pathogenesis of sensorineural hearing loss and screening for preventive and therapeutic drugs.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, alio-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

A method of estimating glomerular filtration rate of a feline can include measuring a blood sample of a feline for blood serum concentrations of pseudouridine and acetylthreonine, and optionally phenylacetylglutamine, and / or tryptophan, and also calculating a blood serum level product. The method can also include applying a feline factor as a multiple to the blood serum level product resulting in an estimated glomerular filtration rate. Calculating the blood serum level product can be based on a first weighted value based upon the blood serum concentration of pseudouridine, a second weighted value based upon the blood serum concentration of acetylthreonine,, an optional third weighted value based upon the blood serum concentration of phenylacetylglutamine, and an optional fourth weighted value based upon the blood serum concentration of tryptophan.

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, dimethylglycine, tryptophan, indoxylsulfate, phenylacetylglutamine, sialic acid, 5-hydroxy-6-indolyl-o-sulfate, 5-(Δ-carboxybutyl) homocysteine, and / or an anion having m / z:RMT:polarity of 345.1553:0.770:n, or determination of metabolites in stool samples, such as ketodeoxycholic acid, cholic acid, choline, tryptophan, trimethyllysine, serine, butyric acid, lactic acid, hypoxanthine and / or guanine.

The present invention relates to a personal care composition. Particularly, the present invention relates to a personal care composition that provides protection from sun-induced damages. The composition comprises a skin care benefit agent selected from acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tyrosine, or a derivative, or a salt, or mixtures thereof, in combination with an oil-soluble sunscreen, a water-soluble sunscreen, and a non-ionic surfactant with select HLB value and select polymers. The composition provides protection from ROS generation induced by exposure to UV and / or blue light.

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m / z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and [GSA×Tyr]: [AHA×(an anion having m / z: RMT: polarity of 160.0615:0.830: n)] ratiometric biomarker.